Lipoprotein(a) levels in patients with unstable angina and their relationship with atherothrombosis and myocardial damage

International Journal of Clinical Practice

Volumn 59, Issue 2, 2005, Pages 150-155

  Yazici, Mustafa ^a   Demircan, S ^a   Durna, K ^a   Sahin, M ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Atherothrombosis; Lipoprotein(a); Myocardial damage; Troponin I; Unstable angina

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; LIPOPROTEIN A; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART MUSCLE INJURY; HOSPITAL ADMISSION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; UNSTABLE ANGINA PECTORIS; VENOUS BLOOD;

ANGINA, UNSTABLE; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TROPONIN I;

EID: 14744290757     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00442.x     Document Type: Article

References (32)

1. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolisation culminating in total vascular occlusion. Circulation 1985; 71: 699-708.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310-8.
3. Terres W, Kummel P, Sudrow A et al. Enhanced coagulation activation in troponin T positive unstable angina pectoris. Am Heart J 1998; 135: 281-6.
4. Hamm CW, Ravkilde J, Gerhardt W et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327 146-50.
5. Benamer H, Steg PG, Benessiano J et al. Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 1999; 137: 815-20.
6. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde notification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267: 4143-51.
7. Loscalzo J, Weinfeld M, Fless G, Scanu AM. Lipoprotein(a), fibrin binding and plasminogen activation. Arteriosclerosis 1990; 10: 240-5.
8. Seed M, Doherty E, Stubbs P. Lipoprotein(a): a prothrombotic risk factor for coronary artery disease. J Cardiovasc Risk 1995; 2: 206-15.
9. Almeda FQ, Calvin JE, Parrillo JE, Sun FG, Barron JT. Prevalence of angiographically significant stenosis in patients with chest pain and an elevated troponin I level and normal creatine kinase and creatine kinase-MB levels. Am J Cardiol 2001; 87: 1286-9.
10. Sanchiz J, Bodi V, Llacer A et al. Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2003; 91: 448-51.
11. Grundy SM, Becker D, Clarck LT et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
12. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51 (3): 606.
13. Eagle KA, Lim MJ, Dabbous OH et al. A validated prediction model for all forms of acute coronary syndrome. Estimating the risk of 6-month post discharge death in an international registry. JAMA 2004; 291: 2727-33.
14. Stubbs P, Seed M, Moseley D et al. A prospective study of the role of lipoprotein(a) in the pathogenesis of unstable angina. Eur Heart J 1997; 18: 603-7.
15. Beisegel U, Niendorf A, Wolf K et al. Lipoprotein(a) in the arterial Wall. Eur Heart J 1990; 11: 174-83.
16. Rainwater DL, McMahan CA, Malcom GT et al. Lipid and apolipoprotein predictors of atherosclerosis in young: Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol 1999; 19: 753-61.
17. Zampoulakis JD, Kyriakousi AA, Poralis KA et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol 2000; 23: 895-900.
18. Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low-density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis 1999; 143: 229-43.
19. Antman EM, Tanasijevic MJ, Thompson B et al. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
20. Mair J, Dienstl F, Puschendorf B. Cardiac troponin T in the diagnosis of myocardial injury. Crit Rev Clin Lab Sci 1992; 29 31-57.
21. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intra-myocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1985; 73 418-27.
22. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Circulation 1989; 80: 17-23.
23. Williams JK, Bellinger DA, Nichols TC et al. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993; 13 548-54.
24. Ichinose A, Suzuki K, Saito T. Apolipoprotein(a) and thrombosis: molecular and genetic bases of hyperlipoprotein(a)-emia. Semin Thromb Hemost 1998; 24: 237-43.
25. Burke AP, Farb A, Malcom GT et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
26. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. Am J Cardiol 1998; 82: 26-33.
27. Palabrica TM, Liu AC, Aronowitz MJ et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-9.
28. Angles-Cano E. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Circulation 2000; 102: E184-5.
29. Poon M, Zhang X, Dunsky KG et al. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514-9.
30. Shlipak MG, Simon JA, Grady D et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001; 38: 705-11.
31. Bersot TP, Pepin GM, Mahley RW. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Am Heart J 2003; 146: 1052-9.
32. Mahley RW, Palaoglu KE, Atak Z et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36 839-59.